Transfection News and Research

RSS

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

Thermo Fisher Scientific offers siRNA libraries in Labcyte Echo qualified source plates

Labcyte Inc., a leader in miniaturization technologies for liquid handling, announced today that Thermo Fisher Scientific, the world leader in serving science, is offering the option for customers to receive siRNA (small-interfering RNA) reagent libraries in Labcyte Echo qualified source plates.

From Thermo Fisher Scientific Inc. 7 Sep 2011

World RNA Interference market will be worth $4 billion by 2017: New report

By 2017, the world RNA Interference market will be worth $4 billion, according to a new report available from companiesandmarkets.com.

5 Aug 2011

Human kinome RNAi screening performed using Roche’s xCELLigence MP Instrument

RNA interference studies are a powerful technology for high-throughput screening. However, endpoint analyses only provide a snapshot of the analyzed cellular phenotype, as it is not possible to measure developmental changes over time.

29 Jul 2011

Scientists convert brain cells into cardiomyocytes

For the past decade, researchers have tried to reprogram the identity of all kinds of cell types. Heart cells are one of the most sought-after cells in regenerative medicine because researchers anticipate that they may help to repair injured hearts by replacing lost tissue.

11 Jul 2011

GeneTex to introduce new Easy-iPSC minicircle DNA vector technology in June

GeneTex, a leading manufacturer of antibodies for research use, is pleased to announce they will be launching several new exciting products in June, including the new Easy-iPSC minicircle DNA vector technology.

9 Jun 2011

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Life Technologies Corporation and ProBioGen AG today announced the availability of Gibco Freedom Cell Line Development Kits, a new line of royalty-free products that integrate cells, reagents, culture media and protocols to bring simplicity and flexibility, eliminating up to two months in the earliest stages of new biological drug development.

17 May 2011

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

Techulon, Inc. announced today that its Glycofect Discovery and Therapeutic Delivery Platform has been awarded United States patent protection. The patented invention provides a new class of non-viral transfection vectors based on synthetic carbohydrate containing polyamides that can be used for both in vivo and in vitro applications.

16 May 2011

Adamis acquires cancer vaccine technology from UCSD

Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.

20 Apr 2011

Scientists effectively combine two methods used as vehicles to carry DNA into cell nuclei

Scientists at Polytechnic Institute of New York University (NYU-Poly) and at the NYU College of Dentistry have discovered a biochemical version of a principle well known among confectioners. Call it the "peanut butter and chocolate" rule: Sometimes two things work better together than alone.

5 Apr 2011

Covaris launches Bench-top SF220 Formulation Processing System

Covaris Incorporated today announced the introduction of the Bench-top SF220 High Performance Formulation Processing System.

25 Mar 2011

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

Positron emission tomography can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine.

1 Feb 2011

Novel AAV gene therapy offers various advantages

A new, simplified method for producing large amounts of viral vector cassettes capable of shuttling genes into host cells will help advance the promising field of gene therapy as applications move into large animal studies and human clinical trials.

6 Jan 2011

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

9 Dec 2010

Roche introduces X-tremeGENE 9, X-tremeGENE HP reagents

Roche announced today the introduction of two new high-performance DNA transfection reagents for its innovative cellular analysis portfolio for life science research.

7 Dec 2010

Life Technologies launches Qubit 2.0 Fluorometer for molecular biology research

Life Technologies Corporation, a provider of innovative life science solutions, today announced the launch of its next-generation Qubit® 2.0 Fluorometer specifically for molecular biology researchers who work with precious samples and perform applications that require a large financial or time investment. The new system quantitates DNA, RNA and protein with accuracy, sensitivity, speed and ease-of-use.

29 Nov 2010

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.

26 Oct 2010

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010

Altogen Biosystems releases PEG-Liposome siRNA In Vivo Transfection Kit

Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.